drugset / Trial / NCT00290550

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

NCT00290550

Phase 2 Terminated 22 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.

Timeline

Start
2006-06
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject TOZASERTIB Small molecule 10 mg/m2 Intravenous